This study was supported by a grant from the Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Original Research Article
Efficacy of Topical Atorvastatin for the Treatment of Pressure Ulcers: A Randomized Clinical Trial
Version of Record online: 12 AUG 2013
© 2013 Pharmacotherapy Publications, Inc.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Volume 34, Issue 1, pages 19–27, January 2014
How to Cite
(Pharmacotherapy 2014;34(1):19–27) doi: 10.1002/phar.1339
Iranian Registry of Clinical Trials identifier: IRCT201102273449N4
- Issue online: 8 JAN 2014
- Version of Record online: 12 AUG 2013
- Pharmaceutical Sciences Research Center
- Iranian Registry of Clinical Trials. Grant Number: IRCT201102273449N4
- pressure ulcer;
To evaluate the effects of topical atorvastatin on the healing process of pressure ulcers in critically ill patients.
Randomized, double-blind, placebo-controlled clinical trial.
Medical-surgical intensive care unit of a university-affiliated teaching hospital in Tehran, Iran.
One hundred four patients with stage I or II pressure ulcers, graded according to the 2-digit Stirling Pressure Sore Severity Scale.
Patients were randomized to receive topical atorvastatin 1% ointment (51 patients [atorvastatin group]) or placebo ointment (53 patients [control group]) applied once/day to pressure ulcers for 14 days in addition to standard care for pressure ulcers.
Measurements and Main Results
The efficacy of each treatment was assessed on days 7 and 14. Efficacy was determined based on the degree of healing of the existing pressure ulcer by using the 2-digit Stirling scale. The baseline stage of the pressure ulcers did not differ significantly between the control and atorvastatin groups. However, the mean ± SD stage of pressure ulcers significantly decreased in the atorvastatin group compared with the control group on day 7 (0.97 ± 0.76 vs 1.74 ± 0.75, p<0.01) and day 14 (0.42 ± 0.67 vs 1.71 ± 0.78, p<0.01) of treatment. In addition, the mean ± SD surface areas of ulcers in the atorvastatin group were significantly declined compared with the control group after 7 days (5.55 ± 4.55 vs 9.41 ± 5.03 cm2, p<0.01) and 14 days (3.72 ± 4.45 vs 10.41 ± 6.41 cm2, p<0.01) of treatment.
Topical application of atorvastatin ointment 1% for 14 days in addition to standard care significantly accelerated the healing of stage I or II pressure ulcers in critically ill patients.